Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Véronique, Blouin"'
Autor:
Magalie Penaud-Budloo, Emilie Lecomte, Quentin Lecomte, Simon Pacouret, Frédéric Broucque, Aurélien Guy-Duché, Jean-Baptiste Dupont, Laurence Jeanson-Leh, Cécile Robin, Véronique Blouin, Eduard Ayuso, Oumeya Adjali
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 32, Iss 3, Pp 101305- (2024)
With more than 130 clinical trials and 8 approved gene therapy products, adeno-associated virus (AAV) stands as one of the most popular vehicles to deliver therapeutic DNA in vivo. One critical quality attribute analyzed in AAV batches is the presenc
Externí odkaz:
https://doaj.org/article/042640a504cc42909af1d623d410fa67
Autor:
Benoit Gautier, Léna Meneux, Nadège Feret, Christine Audrain, Laetitia Hudecek, Alison Kuony, Audrey Bourdon, Caroline Le Guiner, Véronique Blouin, Cécile Delettre, Frédéric Michon
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 27, Iss , Pp 1-16 (2022)
Corneal blindness is the fourth leading cause of blindness worldwide. Since corneal epithelium is constantly renewed, non-integrative gene transfer cannot be used to treat corneal diseases. In many of these diseases, the tear film is defective. Tears
Externí odkaz:
https://doaj.org/article/baf4fa1fac5243f69dd8606da6919555
Autor:
Karim Bey, Johan Deniaud, Laurence Dubreil, Béatrice Joussemet, Joseph Cristini, Carine Ciron, Juliette Hordeaux, Morwenn Le Boulc’h, Kevin Marche, Maud Maquigneau, Michaël Guilbaud, Rosalie Moreau, Thibaut Larcher, Jack-Yves Deschamps, Marion Fusellier, Véronique Blouin, Caroline Sevin, Nathalie Cartier, Oumeya Adjali, Patrick Aubourg, Philippe Moullier, Marie-Anne Colle
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 771-784 (2020)
The identification of the most efficient method for whole central nervous system targeting that is translatable to humans and the safest route of adeno-associated virus (AAV) administration is a major concern for future applications in clinics. Addit
Externí odkaz:
https://doaj.org/article/a0aedb1aca064422b991e72f09f1cc8d
Autor:
Achille François, Mohammed Bouzelha, Emilie Lecomte, Frédéric Broucque, Magalie Penaud-Budloo, Oumeya Adjali, Philippe Moullier, Véronique Blouin, Eduard Ayuso
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 10, Iss , Pp 223-236 (2018)
Although the clinical use of recombinant adeno-associated virus (rAAV) vectors is constantly increasing, the development of suitable quality control methods is still needed for accurate vector characterization. Among the quality criteria, the titrati
Externí odkaz:
https://doaj.org/article/e86bc233d9c34383bc042649c09abbea
Autor:
Sylvie Saleun, Caroline Mas, Aline Le Roy, Magalie Penaud-Budloo, Oumeya Adjali, Véronique Blouin, Christine Ebel
Publikováno v:
European Biophysics Journal
European Biophysics Journal, 2023, ⟨10.1007/s00249-023-01650-3⟩
European Biophysics Journal, 2023, ⟨10.1007/s00249-023-01650-3⟩
Recombinant adeno-associated virus virus-derived vectors (rAAVs) are among the most used viral delivery system for in vivo gene therapies with a good safety profile. However, rAAV production methods often lead to a heterogeneous vector population, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e134da0f42e5f62217ca29765f12f9d2
https://doi.org/10.1007/s00249-023-01650-3
https://doi.org/10.1007/s00249-023-01650-3
Autor:
Audrey Bourdon, Virginie François, Liwen Zhang, Aude Lafoux, Bodvael Fraysse, Gilles Toumaniantz, Thibaut Larcher, Tiphaine Girard, Mireille Ledevin, Cyrielle Lebreton, Agnès Hivonnait, Anna Creismeas, Marine Allais, Basile Marie, Justine Guguin, Véronique Blouin, Séverine Remy, Ignacio Anegon, Corinne Huchet, Alberto Malerba, Betty Kao, Anita Le Heron, Philippe Moullier, George Dickson, Linda Popplewell, Oumeya Adjali, Federica Montanaro, Caroline Le Guiner
Publikováno v:
Gene Therapy. 29:520-535
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d9c1614fc49440d97af2761d82421d2
https://doi.org/10.1038/s41434-022-00317-6
https://doi.org/10.1038/s41434-022-00317-6
Autor:
Emilie Lecomte, Benoît Tournaire, Benjamin Cogné, Jean-Baptiste Dupont, Pierre Lindenbaum, Mélanie Martin-Fontaine, Frédéric Broucque, Cécile Robin, Matthias Hebben, Otto-Wilhelm Merten, Véronique Blouin, Achille François, Richard Redon, Philippe Moullier, Adrien Léger
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 4, Iss C (2015)
Recent successful clinical trials with recombinant adeno-associated viral vectors (rAAVs) have led to a renewed interest in gene therapy. However, despite extensive developments to improve vector-manufacturing processes, undesirable DNA contaminants
Externí odkaz:
https://doaj.org/article/741f46340a074fda945084019638521d
Autor:
Mirja Hommel, Dimitri Alvarez-Dorta, Oumeya Adjali, Aurélien Leray, Eduard Ayuso, Gloria González-Aseguinolaza, Simon Pacouret, Mickaël Guilbaud, Mohammed Bouzelha, Philippe Moullier, Sébastien G. Gouin, Laurence Dubreil, Mathieu Mével, Véronique Blouin, Jean Philippe Combal, David Deniaud, Magalie Penaud-Budloo
Publikováno v:
Chemical Science
Chemical Science, The Royal Society of Chemistry, 2020, 11 (4), pp.1122-1131. ⟨10.1039/C9SC04189C⟩
Chemical Science, 2020, 11 (4), pp.1122-1131. ⟨10.1039/C9SC04189C⟩
Chemical Science, The Royal Society of Chemistry, 2020, 11 (4), pp.1122-1131. ⟨10.1039/C9SC04189C⟩
Chemical Science, 2020, 11 (4), pp.1122-1131. ⟨10.1039/C9SC04189C⟩
Gene delivery vectors based on adeno-associated virus (AAV) are highly promising due to several desirable features of this parent virus, including a lack of pathogenicity, efficient infection of dividing and non-dividing cells and sustained maintenan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87a9713574e18c368d03437b10a2f8f6
https://pubmed.ncbi.nlm.nih.gov/34084369
https://pubmed.ncbi.nlm.nih.gov/34084369
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 1, Iss C (2014)
Vectors based on recombinant adeno-associated viruses (rAAV) attract a growing interest for human gene therapy. Recently, it was shown that many rAAV serotypes produced by transient transfection of human embryonic kidney 293 cell line (HEK293) are ef
Externí odkaz:
https://doaj.org/article/571489f5df1c4a6fb1aa395317632f9e
Autor:
Audrey, Bourdon, Virginie, François, Liwen, Zhang, Aude, Lafoux, Bodvael, Fraysse, Gilles, Toumaniantz, Thibaut, Larcher, Tiphaine, Girard, Mireille, Ledevin, Cyrielle, Lebreton, Agnès, Hivonnait, Anna, Creismeas, Marine, Allais, Basile, Marie, Justine, Guguin, Véronique, Blouin, Séverine, Remy, Ignacio, Anegon, Corinne, Huchet, Alberto, Malerba, Betty, Kao, Anita, Le Heron, Philippe, Moullier, George, Dickson, Linda, Popplewell, Oumeya, Adjali, Federica, Montanaro, Caroline, Le Guiner
Publikováno v:
Gene therapy. 29(9)
Duchenne muscular dystrophy (DMD) is a muscle wasting disorder caused by mutations in the gene encoding dystrophin. Gene therapy using micro-dystrophin (MD) transgenes and recombinant adeno-associated virus (rAAV) vectors hold great promise. To overc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::932d0ee578a32dab628daaac46e8bb2b
https://pubmed.ncbi.nlm.nih.gov/35449294
https://pubmed.ncbi.nlm.nih.gov/35449294